Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Immunother ; 20(3): 202-7, 1997 May.
Artículo en Inglés | MEDLINE | ID: mdl-9181458

RESUMEN

High doses of tumor necrosis factor-alpha (TNF) seem to be effective in the treatment of solid tumors in the extremities. By applying current intensive care technology, systemic administration of high doses of TNF levels might be feasible for the treatment of cancer in other localizations. To establish the early and late effects of high systemic TNF levels on the lungs, we determined lung function parameters in 12 patients before and after hyperthermic isolated limb perfusion (HILP) with TNF and melphalan. Because of leakage during perfusion, mean maximum systemic TNF levels of 60.0 ng/ml (range, 0.3-356 ng/ml) were obtained. Significant alterations in the vital capacity (VC), the capillary blood volume (Vc), the diffusing capacity of the alveolocapillary membrane (Dm), and the transfer capacity of the lungs for carbon monoxide per unit alveolar volume (KCO) were observed 1 week after HILP. Eight weeks after HILP, they returned to pretreatment value. Alterations in lung functions were not related to the maximum systemic TNF level. In conclusion, disturbances in pulmonary functions are observed in patients after HILP with TNF and melphalan. These disturbances, which are probably partly caused by high systemic TNF levels, are reversible and would not preclude administration of systemic TNF in high doses.


Asunto(s)
Brazo , Quimioterapia del Cáncer por Perfusión Regional , Hipertermia Inducida , Pierna , Melfalán/uso terapéutico , Pruebas de Función Respiratoria , Factor de Necrosis Tumoral alfa/uso terapéutico , Adulto , Anciano , Neoplasias de la Mama/fisiopatología , Neoplasias de la Mama/cirugía , Quimioterapia del Cáncer por Perfusión Regional/efectos adversos , Femenino , Humanos , Hipertermia Inducida/efectos adversos , Masculino , Mastectomía/efectos adversos , Melanoma/tratamiento farmacológico , Melanoma/fisiopatología , Melfalán/efectos adversos , Persona de Mediana Edad , Sarcoma/tratamiento farmacológico , Sarcoma/fisiopatología , Neoplasias Cutáneas/tratamiento farmacológico , Neoplasias Cutáneas/fisiopatología , Neoplasias de los Tejidos Blandos/tratamiento farmacológico , Neoplasias de los Tejidos Blandos/fisiopatología , Factor de Necrosis Tumoral alfa/efectos adversos , Factor de Necrosis Tumoral alfa/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA